| Abstrakt: |
A study conducted at the University of Medicine and Pharmacy Iuliu Hatieganu in Cluj Napoca, Romania, investigated the efficacy of a pro-re-nata regimen (PRN) for neovascular age-related macular degeneration (nAMD). The study found that Brolucizumab injections had a low rate of adverse reactions and resulted in a significant reduction of retinal fluid, particularly subretinal fluid. The interval of injection (INTOI) was calculated to be 2.68, which could be an important parameter for future characterization of Brolucizumab and other anti-VEGF therapies. Additionally, Brolucizumab showed promise in the treatment of chronic central serous chorioretinopathy (CSC). [Extracted from the article] |
